Category Archives: Biotech

In our last piece about Premier Biomedical Inc (OTCMKTS:BIEI), we explained that the company had retired the convertible debt held on the books. The market appreciated this move, because the financial risk of the company was drastically reduced....

Atossa Genetics Inc (NASDAQ:ATOS) hasn’t had a good 2017 so far. The company is currently trading for around $0.50 a share, down 65% on its 2017 open price. Over the last couple of days, however, Atossa has picked up a little bit of strength,...

On May 23, 2017, Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced that it’s poised to present data from its lead cystic fibrosis (CF) study at the upcoming European Cystic Fibrosis Society Conference. On the back of the news, the...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has taken a hit on its most recent announcement, with the company currently trading at a close to 10% discount to its session open pricing. The decline comes on the back of the news that management...

Since its IPO last year, Kadmon Holdings Inc (NYSE:KDMN) has lost close to 75% of its market capitalization. The latest news is that the company is the subject of a couple of investigations (shareholder rights, LLP-type investigations; not...

Back on May 10, we published this piece asking the question: Is The Elite Pharmaceuticals Inc (OTCMKTS:ELTP) Data About To Hit Press? The data we were referring to was from a bioequivalent study of its lead development outside, an abuse-deterrent...

EnteroMedics Inc (NASDAQ:ETRM) just put out its latest earnings and management hosted a conference call to discuss the results. Alongside the pre-prepared remarks, the team also fielded questions. Deriving from both the call itself and the...

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) has not had a great 2017. The company is down close to 40% year to date and trades at a more than 70% discount to its January highs. The surfacing of stock manipulation claims that hit press in...

In our first article about ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), we pointed out that the company’s drugs TXL™, Valnivudine, and CRV431 were close to Phase 3 and the company had attracted the attention of some big institutions....

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) took a hit last week when the company announced its first quarter 2017 financials. During a subsequent conference call, however, management was able to ease sentiment a little, and Pernix will kick...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter